Skip to main content
Fig. 1 | Cost Effectiveness and Resource Allocation

Fig. 1

From: Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration

Fig. 1

Decision strategies: intervention regimen provides pemigatinib 13.5 mg per day, comparator 1 provides mFOLFOX a, comparator 2 provides 5-FU b, and the cost-effectiveness analysis framework c. ICC intrahepatic cholangiocarcinoma, FGFR2 fibroblast growth factor receptor 2, mFOLFOX a combination of oxaliplatin, folinic acid, and fluorouracil, 5-FU fluorouracil, ICER incremental cost-effectiveness ratio, INMB incremental net monetary benefit, EVPI expected value of perfect information

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us